Literature DB >> 23362135

Tumor localization and biochemical response to cure in tumor-induced osteomalacia.

William H Chong1, Panagiota Andreopoulou, Clara C Chen, James Reynolds, Lori Guthrie, Marilyn Kelly, Rachel I Gafni, Nisan Bhattacharyya, Alison M Boyce, Diala El-Maouche, Diana Ovejero Crespo, Richard Sherry, Richard Chang, Felasfa M Wodajo, Gad B Kletter, Andrew Dwyer, Michael T Collins.   

Abstract

Tumor-induced osteomalacia (TIO) is a rare disorder of phosphate wasting due to fibroblast growth factor-23 (FGF23)-secreting tumors that are often difficult to locate. We present a systematic approach to tumor localization and postoperative biochemical changes in 31 subjects with TIO. All had failed either initial localization, or relocalization (in case of recurrence or metastases) at outside institutions. Functional imaging with ¹¹¹Indium-octreotide with single photon emission computed tomography (octreo-SPECT or SPECT/CT), and ¹⁸fluorodeoxyglucose positron emission tomography/CT (FDG-PET/CT) were performed, followed by anatomic imaging (CT, MRI). Selective venous sampling (VS) was performed when multiple suspicious lesions were identified or high surgical risk was a concern. Tumors were localized in 20 of 31 subjects (64.5%). Nineteen of 20 subjects underwent octreo-SPECT imaging, and 16 of 20 FDG-PET/CT imaging. Eighteen of 19 (95%) were positive on octreo-SPECT, and 14 of 16 (88%) on FDG-PET/CT. Twelve of 20 subjects underwent VS; 10 of 12 (83%) were positive. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were as follows: sensitivity = 0.95, specificity = 0.64, PPV = 0.82, and NPV = 0.88 for octreo-SPECT; sensitivity = 0.88, specificity = 0.36, PPV = 0.62, and NPV = 0.50 for FDG-PET/CT. Fifteen subjects had their tumor resected at our institution, and were disease-free at last follow-up. Serum phosphorus returned to normal in all subjects within 1 to 5 days. In 10 subjects who were followed for at least 7 days postoperatively, intact FGF23 (iFGF23) decreased to near undetectable within hours and returned to the normal range within 5 days. C-terminal FGF23 (cFGF23) decreased immediately but remained elevated, yielding a markedly elevated cFGF23/iFGF23 ratio. Serum 1,25-dihydroxyvitamin D₃ (1,25D) rose and exceeded the normal range. In this systematic approach to tumor localization in TIO, octreo-SPECT was more sensitive and specific, but in many cases FDG-PET/CT was complementary. VS can discriminate between multiple suspicious lesions and increase certainty prior to surgery. Sustained elevations in cFGF23 and 1,25D were observed, suggesting novel regulation of FGF23 processing and 1,25D generation.
Copyright © 2013 American Society for Bone and Mineral Research.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23362135      PMCID: PMC3900247          DOI: 10.1002/jbmr.1881

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  20 in total

1.  Usefulness of 201Tl and 99mTc MIBI scintigraphy in a case of oncogenic osteomalacia.

Authors:  Takao Kimizuka; Yutaka Ozaki; Yukiharu Sumi
Journal:  Ann Nucl Med       Date:  2004-02       Impact factor: 2.668

2.  The importance of whole body imaging in tumor-induced osteomalacia.

Authors:  William H Chong; Sahzene Yavuz; Shrita M Patel; Clara C Chen; Michael T Collins
Journal:  J Clin Endocrinol Metab       Date:  2011-12       Impact factor: 5.958

3.  Tumor-induced osteomalacia.

Authors:  Suzanne M Jan de Beur
Journal:  JAMA       Date:  2005-09-14       Impact factor: 56.272

4.  Detection of a mesenchymal tumor responsible for hypophosphatemic osteomalacia using FDG-PET.

Authors:  Jean-Louis Dupond; Hakim Mahammedi; Nadine Magy; Olaf Blagosklonov; Nadine Meaux-Ruault; Bernadette Kantelip
Journal:  Eur J Intern Med       Date:  2005-10       Impact factor: 4.487

Review 5.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

6.  Bone scan in tumor-induced osteomalacia.

Authors:  H K Lee; W W Sung; P Solodnik; M Shimshi
Journal:  J Nucl Med       Date:  1995-02       Impact factor: 10.057

7.  Tumor-induced osteomalacia: clinical and basic studies.

Authors:  E Shane; M Parisien; J E Henderson; D W Dempster; F Feldman; M A Hardy; J F Tohme; A C Karaplis; T L Clemens
Journal:  J Bone Miner Res       Date:  1997-09       Impact factor: 6.741

8.  Case records of the Massachusetts General Hospital. Case 33-2011. A 56-year-old man with hypophosphatemia.

Authors:  Clemens Bergwitz; Michael T Collins; Ravi S Kamath; Andrew E Rosenberg
Journal:  N Engl J Med       Date:  2011-10-27       Impact factor: 91.245

9.  Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active.

Authors:  Takashi Shimada; Itaru Urakawa; Tamara Isakova; Yuji Yamazaki; Michael Epstein; Katherine Wesseling-Perry; Myles Wolf; Isidro B Salusky; Harald Jüppner
Journal:  J Clin Endocrinol Metab       Date:  2009-12-04       Impact factor: 5.958

10.  Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia.

Authors:  Michèle Duet; Samar Kerkeni; Raja Sfar; Cécile Bazille; Frédéric Lioté; Philippe Orcel
Journal:  Clin Nucl Med       Date:  2008-11       Impact factor: 7.794

View more
  42 in total

1.  Successful Localization Using 68Ga-DOTATOC PET/CT of a Phosphaturic Mesenchymal Tumor Causing Osteomalacia in a Patient with Concurrent Follicular Lymphoma.

Authors:  Sejin Ha; Sujin Park; Hyunji Kim; Heounjeong Go; Seung Hun Lee; Ji Yoon Choi; Jung Yong Hong; Jin-Sook Ryu
Journal:  Nucl Med Mol Imaging       Date:  2018-09-12

2.  "Slow and steady wins the race": the importance of perseverance in the management of oncogenic osteomalacia.

Authors:  Maria Manara; Luigi Sinigaglia
Journal:  Endocrine       Date:  2016-11-29       Impact factor: 3.633

3.  Imaging features of phosphaturic mesenchymal tumors.

Authors:  Stephen M Broski; Andrew L Folpe; Doris E Wenger
Journal:  Skeletal Radiol       Date:  2018-07-09       Impact factor: 2.199

Review 4.  What is new about the molecular genetics in matrix-producing soft tissue tumors? -The contributions to pathogenetic understanding and diagnostic classification.

Authors:  Yu-Chien Kao; Jen-Chieh Lee; Hsuan-Ying Huang
Journal:  Virchows Arch       Date:  2019-11-07       Impact factor: 4.064

5.  Stability and degradation of fibroblast growth factor 23 (FGF23): the effect of time and temperature and assay type.

Authors:  D El-Maouche; C E Dumitrescu; P Andreopoulou; R I Gafni; B A Brillante; N Bhattacharyya; N S Fedarko; M T Collins
Journal:  Osteoporos Int       Date:  2016-02-29       Impact factor: 4.507

6.  Reports of 17 Chinese patients with tumor-induced osteomalacia.

Authors:  Wei-Jia Yu; Jin-Wei He; Wen-Zhen Fu; Chun Wang; Zhen-Lin Zhang
Journal:  J Bone Miner Metab       Date:  2016-04-16       Impact factor: 2.626

Review 7.  Tumor-Induced Osteomalacia.

Authors:  Pablo Florenzano; Iris R Hartley; Macarena Jimenez; Kelly Roszko; Rachel I Gafni; Michael T Collins
Journal:  Calcif Tissue Int       Date:  2020-06-05       Impact factor: 4.333

8.  Targeted FGFR Blockade for the Treatment of Tumor-Induced Osteomalacia.

Authors:  Iris R Hartley; Carole B Miller; Georgios Z Papadakis; Clemens Bergwitz; Jaydira Del Rivero; Jenny E Blau; Pablo Florenzano; Jason A Berglund; Jing Tassone; Kelly L Roszko; Susan Moran; Rachel I Gafni; Randi Isaacs; Michael T Collins
Journal:  N Engl J Med       Date:  2020-09-09       Impact factor: 91.245

9.  Diagnostic performance and impact on patient management of 68Ga-DOTA-TOC PET/CT for detecting osteomalacia-associated tumours.

Authors:  Marie Paquet; Mathieu Gauthé; Jules Zhang Yin; Valérie Nataf; Ophélie Bélissant; Philippe Orcel; Christian Roux; Jean-Noël Talbot; Françoise Montravers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-03-12       Impact factor: 9.236

10.  68Ga-DOTATATE for Tumor Localization in Tumor-Induced Osteomalacia.

Authors:  Diala El-Maouche; Samira M Sadowski; Georgios Z Papadakis; Lori Guthrie; Candice Cottle-Delisle; Roxanne Merkel; Corina Millo; Clara C Chen; Electron Kebebew; Michael T Collins
Journal:  J Clin Endocrinol Metab       Date:  2016-08-17       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.